DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced plans to proceed to a Phase 3 clinical program to evaluate epinastine nasal spray for the treatment of allergic rhinitis, following a productive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
